JavaScript 似乎在您的浏览器中被禁用。 为了您在我们网站能获得最好的体验，建议在浏览器中打开Javascript。

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

跳转到图像库的开头

SepMate™-50 (IVD)

用于体外诊断(IVD)应用的密度梯度离心管

只有 %1 左

率先评论此产品

¥4,978.00

产品号 #（选择产品）

产品号 #85450_C

用于体外诊断(IVD)应用的密度梯度离心管

产品优势

无需小心地将血液铺在密度梯度离心液（如Lymphoprep™等）上
使用新鲜样本时，总离心时间可缩短至10分钟（打开刹车）
只需简单倾倒上清液即可快速轻松地收集分离的单个核细胞
可与RosetteSep™富集试剂联合使用，在30分钟内分离特定的细胞类型

产品组分包括

SepMate™-50 (IVD)，100支装（产品号 #85450)
- 每盒含4袋，每袋25支管
SepMate™-50 (IVD)，500支装（产品号 #85460）
- 每盒含4袋，每袋25支管（产品号 #85450）× 5盒

立即询价

Try SepMate™-50 (IVD) tubes for density gradient centrifugation in your IVD applications. Request a Sample

要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。

Lymphoprep™

What Our Scientist Says

Traditional isolation of PBMCs requires careful layering of blood onto density gradient media prior to centrifugation. We developed SepMate™ to simplify this process, so anyone can isolate PBMCs with a simple pour while maintaining consistency across samples.

Peter MorinTechnical Scientist

总览

实验数据

产品说明书及文档

应用领域

总览

通过在密度梯度离心步骤中使用SepMate™，可简化外周血单个核细胞（PBMCs）的分离过程。

SepMate™离心管内含有一个隔离插件，用于在密度梯度离心液与血液之间形成屏障，从而无需小心地分层加入血液样本，用户通过简单的倾倒即可轻松收集单个核细胞。本产品可与RosetteSep™配合使用，以分离特定的免疫细胞亚群。

SepMate™-50设计用于处理4至17 mL的样本。

SepMate™按照cGMP标准生产，并在澳大利亚、加拿大、欧盟、韩国、瑞士、土耳其、英国和美国以体外诊断（IVD）设备提供。在中国，SepMate™被国家药品监督管理局（NMPA）认定为通用实验室设备。最终用户有责任确定该产品是否适用于其特定应用。

浏览SepMate™常见问题（FAQs）了解更多信息。

包含
含有插件的聚丙烯管

分类
离心管

细胞类型
B细胞，树突状细胞（DCs），单核细胞，单个核细胞，NK细胞，T细胞，CD4+ T细胞，CD8+ T细胞，其他T细胞亚群，调节性T细胞

种属
人

样本来源
骨髓、全血

分选方法
负选

应用
细胞分选，体外诊断

品牌
SepMate

研究领域
嵌合体，HLA，免疫

查看更多显示更少

实验数据

PBMC recovery from fresh whole blood using SepMate™-50 versus standard density gradient centrifugation. Graph also shows PBMC recovery from a 48 hour-old sample using SepMate™. n in each group = 7

Figure 1. Recovery of mononuclear cells (MNCs) from peripheral blood using SepMate™-50 versus standard density gradient centrifiguation. Recovery of MNCs from fresh and 48-hour post blood draw enriched by density gradient centrifugation with SepMate™ (purple) or without (grey). There was no significant difference in the recovery of MNCS with and without SepMate™.

Figure 2. Human CD4+ T Cell Isolation using SepMate™-50 and RosetteSep™ Human CD4+ T Cell Enrichment Cocktail

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

SepMate™-50 (IVD)

Catalog #

85450, 85460

Lot #

All

Language

MULTI

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for B Cell Research

Cell Sourcing

Cell Isolation

Cell Expansion

Cell Characterization

Workflow Stages for Dendritic Cell Research

Cell Sourcing

Cell Isolation

Cell Differentiation and Maturation

Cell Characterization

Workflow Stages for Human Pluripotent Stem Cell Research

Reprogramming

Maintenance

Differentiation

Workflow Stages for Hematopoietic Stem and Progenitor Cell Research

Cell Sourcing and Isolation

Expansion and Differentiation

Analysis

Workflow Stages for Total Lymphocyte Research

Cell Sourcing

Cell Isolation

Cell Characterization

Workflow Stages for Monocyte Research

Cell Sourcing

Cell Isolation

Cell Differentiation and Maturation

Cell Characterization

Workflow Stages for Natural Killer Cell Research

Cell Sourcing

Cell Isolation

Cell Expansion and Differentiation

Cell Characterization

Workflow Stages for T Cell Research

Cell Sourcing

Cell Isolation

Cell Activation, Expansion, and Differentiation

Cell Characterization

Workflow Stages for HLA Analysis

Cell Isolation

Characterization

Workflow Stages for Chimerism Analysis

Cell Isolation

Characterization

相关材料与文献

In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. Maranville JC et al. Journal of Crohn's & colitis 2014 NOV

Abstract

BACKGROUND Glucocorticoids (GCs) are steroid hormones used to induce remission in moderate-to-severe inflammatory bowel disease (IBD). A substantial fraction of patients do not respond to GC treatment and require alternate therapies or surgery. At present,non-response can only be assessed empirically by observing continued disease activity. METHODS To identify potential biomarkers of GC response,we retrospectively identified and recruited 18 GC-responsive and 18 GC-nonresponsive IBD patients. This sample included 14 patients with ulcerative colitis (UC) and 22 patients with Crohn's disease (CD),all previously treated with steroids. In peripheral blood mononuclear cells from each patient,we performed in vitro assays to measure GC inhibition of three different immune stimulants (phytohemagglutinin [PHA],α-CD3/α-CD28,and lipopolysaccharide [LPS]). RESULTS In both diseases,we found that inhibition of PHA-mediated T cell proliferation was significantly associated with clinical GC response (P=0.04). Inhibition of proliferation due to direct T cell receptor stimulation using α-CD3/α-CD28 was also significantly associated with clinical GC response in UC patients (P=0.009),but not in CD patients (P=0.78). Interestingly,inhibition of LPS-mediated cytokine secretion showed the strongest association with clinical GC response across both diseases (P=0.005). CONCLUSIONS We show that inhibition of LPS stimulation is more strongly associated with clinical GC response in IBD patients than inhibition of PHA and α-CD3/α-CD28-mediated proliferation. These results support an important role of bacterial recognition and innate immunity in the etiology of IBD. This assay could be a powerful predictor of clinical response to GCs.

View publication

A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. M. K. Wetzel-Smith et al. Nature medicine 2014 DEC

Abstract

We have identified a rare coding mutation,T835M (rs137875858),in the UNC5C netrin receptor gene that segregated with disease in an autosomal dominant pattern in two families enriched for late-onset Alzheimer's disease and that was associated with disease across four large case-control cohorts (odds ratio = 2.15,Pmeta = 0.0095). T835M alters a conserved residue in the hinge region of UNC5C,and in vitro studies demonstrate that this mutation leads to increased cell death in human HEK293T cells and in rodent neurons. Furthermore,neurons expressing T835M UNC5C are more susceptible to cell death from multiple neurotoxic stimuli,including $\beta$-amyloid (A$\beta$),glutamate and staurosporine. On the basis of these data and the enriched hippocampal expression of UNC5C in the adult nervous system,we propose that one possible mechanism in which T835M UNC5C contributes to the risk of Alzheimer's disease is by increasing susceptibility to neuronal cell death,particularly in vulnerable regions of the Alzheimer's disease brain.

View publication

Establishing the pig as a large animal model for vaccine development against human cancer. N. H. Overgaard et al. Frontiers in genetics 2015

Abstract

Immunotherapy has increased overall survival of metastatic cancer patients,and cancer antigens are promising vaccine targets. To fulfill the promise,appropriate tailoring of the vaccine formulations to mount in vivo cytotoxic T cell (CTL) responses toward co-delivered cancer antigens is essential. Previous development of therapeutic cancer vaccines has largely been based on studies in mice,and the majority of these candidate vaccines failed to induce therapeutic responses in the subsequent human clinical trials. Given that antigen dose and vaccine volume in pigs are translatable to humans and the porcine immunome is closer related to the human counterpart,we here introduce pigs as a supplementary large animal model for human cancer vaccine development. IDO and RhoC,both important in human cancer development and progression,were used as vaccine targets and 12 pigs were immunized with overlapping 20mer peptides spanning the entire porcine IDO and RhoC sequences formulated in CTL-inducing adjuvants: CAF09,CASAC,Montanide ISA 51 VG,or PBS. Taking advantage of recombinant swine MHC class I molecules (SLAs),the peptide-SLA complex stability was measured for 198 IDO- or RhoC-derived 9-11mer peptides predicted to bind to SLA-1(*)04:01,-1(*)07:02,-2(*)04:01,-2(*)05:02,and/or -3(*)04:01. This identified 89 stable (t½ ≥ 0.5 h) peptide-SLA complexes. By IFN-$\gamma$ release in PBMC cultures we monitored the vaccine-induced peptide-specific CTL responses,and found responses to both IDO- and RhoC-derived peptides across all groups with no adjuvant being superior. These findings support the further use of pigs as a large animal model for vaccine development against human cancer.

View publication

View All Publications

物种	人
Contains	Polypropylene tube containing an insert
样本来源	全血, 骨髓
Selection Method	Negative